Sophie Cousin1, Sophie Taieb, Nicolas Penel. 1. General Oncology Department, Oscar Lambret Cancer Center, Research Unit EA 2694, Medical School, Lille-Nord-de-France University, Lille, France.
Abstract
PURPOSE OF REVIEW: To describe the difficulty in assessing the biological activity of a novel agent in phase II trials. RECENT FINDINGS: Two major fields of research provide interesting new potential endpoints: endpoints based on new imaging techniques (e.g. PET or spectral imaging that explore tumour metabolism, dynamic contrast enhanced (DCE) ultrasonography or DCE-MRI that explore tumour vascularization and tumour growth inhibition) and endpoints integrating assessment of tumour burden across time, such as the growth modulation index. SUMMARY: Most of the recently described techniques appear attractive, but require formal validation.
PURPOSE OF REVIEW: To describe the difficulty in assessing the biological activity of a novel agent in phase II trials. RECENT FINDINGS: Two major fields of research provide interesting new potential endpoints: endpoints based on new imaging techniques (e.g. PET or spectral imaging that explore tumour metabolism, dynamic contrast enhanced (DCE) ultrasonography or DCE-MRI that explore tumour vascularization and tumour growth inhibition) and endpoints integrating assessment of tumour burden across time, such as the growth modulation index. SUMMARY: Most of the recently described techniques appear attractive, but require formal validation.
Authors: N Penel; G D Demetri; J Y Blay; S Cousin; R G Maki; S P Chawla; I Judson; M von Mehren; P Schöffski; J Verweij; P Casali; S Rodenhuis; H J Schütte; A Cassar; J Gomez; A Nieto; P Zintl; M J Pontes; A Le Cesne Journal: Ann Oncol Date: 2012-11-01 Impact factor: 32.976
Authors: Andreas Mock; Christoph E Heilig; Simon Kreutzfeldt; Daniel Huebschmann; Christoph Heining; Evelin Schröck; Benedikt Brors; Albrecht Stenzinger; Dirk Jäger; Richard Schlenk; Hanno Glimm; Stefan Fröhling; Peter Horak Journal: ESMO Open Date: 2019-11-13